跳转至内容
Merck
CN

T1423000

噻氯匹定 盐酸盐

European Pharmacopoeia (EP) Reference Standard

别名:

5-(邻氯苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C14H14ClNS · HCl
化学文摘社编号:
分子量:
300.25
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

噻氯匹定 盐酸盐, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C14H14ClNS.ClH/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14;/h1-4,6,8H,5,7,9-10H2;1H

SMILES string

Cl.Clc1ccccc1CN2CCc3sccc3C2

InChI key

MTKNGOHFNXIVOS-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

ticlopidine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... P2RY12(64805)

正在寻找类似产品? 访问 产品对比指南

Application

Ticlopidine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Stephen D Wiviott et al.
Lancet (London, England), 382(9892), 605-613 (2013-08-21)
Treatment with prasugrel and aspirin improves outcomes compared with clopidogrel and aspirin for patients with acute coronary syndrome who have had angiography and percutaneous coronary intervention; however, no clear benefit has been shown for patients managed first with drugs only.
Morten Lamberts et al.
Circulation, 129(15), 1577-1585 (2014-01-29)
The optimal long-term antithrombotic treatment of patients with coexisting atrial fibrillation and stable coronary artery disease is unresolved, and commonly, a single antiplatelet agent is added to oral anticoagulation. We investigated the effectiveness and safety of adding antiplatelet therapy to
Willibald Hochholzer et al.
Journal of the American College of Cardiology, 64(4), 361-368 (2014-07-26)
The degree of antiplatelet response to clopidogrel has been associated with clinical outcomes. Studies have investigated whether adjustment of antiplatelet therapies based on a single platelet function test is beneficial. The aim of the study was to test the stability
Julie A Johnson et al.
Pharmacological reviews, 65(3), 987-1009 (2013-05-21)
The past decade has seen tremendous advances in our understanding of the genetic factors influencing response to a variety of drugs, including those targeted at treatment of cardiovascular diseases. In the case of clopidogrel, warfarin, and statins, the literature has
Nohra Chalouhi et al.
Stroke, 45(1), 54-58 (2013-11-21)
Flow diverters are currently indicated for treatment of large and complex intracranial aneurysms. The purpose of this study was to determine whether the indications of flow diversion can be safely extended to unruptured, small, saccular aneurysms (<10 mm) of the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持